Treatment
Empagliflozin clinical trials
We’re tracking 90 recruiting studies that include Empagliflozin, each written for real people, not researchers, below.
Recruiting studies
- NCT06894784RecruitingPhase 3
Combining two diabetes drugs with an automated insulin pump
This trial tests if adding semaglutide and empagliflozin to your automated insulin delivery system (like a smart pump) can improve blood sugar control for adults with type 1 diabetes. It may help with both glucose levels and weight management.
Montreal, QuebecAges 18 years+ - NCT05138575RecruitingPhase 2
Testing SGLT2 pill and potassium nitrate for heart failure with preserved EF
This trial studies whether two medicines—an SGLT2 inhibitor and potassium nitrate—can improve symptoms and heart function in people with heart failure with preserved ejection fraction (HFpEF). It focuses on people who still have signs of “stiff” or high filling pressure in the heart despite a normal-ish ejection fraction.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05671991RecruitingPhase 4
Empagliflozin study for kidney and belly membrane function
This trial tests whether empagliflozin improves kidney health and the function of the belly’s dialysis membrane in people with end-stage kidney disease who do peritoneal dialysis. It may help by changing how well the peritoneal dialysis system works and how the kidneys perform over time.
New Haven, ConnecticutAges 18 years+ - NCT07053319RecruitingPhase 1
Study of diabetes drugs and ketones
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
San Antonio, TexasAges 30–75 - NCT06030843RecruitingPhase 2/Phase 3
Testing empagliflozin for heart and kidney health
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
Bangkok, PathumwanAges 18 years+ - NCT06989723RecruitingPhase 4
Pioglitazone and empagliflozin for fatty liver in type 2 diabetes
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
Seongnam-siAges 20 years+ - NCT07322237RecruitingPhase 4
Study on heart function drugs for liver cirrhosis patients
This trial tests two heart medications, carvedilol and empagliflozin, to see if they improve heart function in people with cirrhosis (liver scarring). It might help those who have early signs of heart stiffness but normal pumping strength.
ChandigarhAges 18–65 - NCT07452913Enrolling by invitationPhase 4
Comparing Diabetes Drug Combinations in Newly Treated Adults
This trial compares two different combinations of diabetes pills (metformin plus empagliflozin with either sitagliptin or linagliptin) in people with type 2 diabetes who have not been treated before. It aims to see which combination works better and is safer for controlling blood sugar.
Karachi, SindhAges 30–55 - NCT07038356RecruitingPhase 3
Continuing empagliflozin during heart failure hospitalizations
This study tests whether continuing empagliflozin (a heart failure medicine) during a hospital stay for heart failure is beneficial compared to stopping it. Participation may help improve recovery and reduce complications.
Jena, ThuringiaAges 18 years+ - NCT06935370RecruitingPhase 3
Testing vicadrostat with empagliflozin for heart failure with weak pump
This trial tests a new drug called vicadrostat combined with another drug, empagliflozin, for people with heart failure and a weak heart pump. It aims to see if this combination helps improve symptoms and outcomes.
Beverly Hills, CaliforniaAges 18 years+ - NCT06531824RecruitingPhase 3
Heart and kidney protection study for chronic kidney disease
This study tests a new medicine (BI 690517) combined with empagliflozin to see if it can help protect the heart and kidneys in people with chronic kidney disease. It may slow down kidney disease progression and reduce heart risks.
Huntsville, AlabamaAges 18 years+ - NCT05726032RecruitingPhase 2
Empagliflozin for fluid buildup from cirrhosis
This Phase 2 study tests empagliflozin to see if it can improve fluid buildup (ascites) in people with cirrhosis. It may help reduce symptoms related to fluid retention, but you must meet specific safety and stability requirements.
New Haven, ConnecticutAges 18 years+ - NCT07107945RecruitingPhase 3
Study of empagliflozin for children with chronic kidney disease
This trial tests if empagliflozin, a daily pill, is safe and helps children ages 2–17 with chronic kidney disease (CKD). Your child may be eligible if they have reduced kidney function and elevated protein in their urine, and are already on stable kidney treatments.
Birmingham, AlabamaAges 2–17 - NCT07064473RecruitingPhase 3
Testing vicadrostat plus empagliflozin for diabetes, high blood pressure, and heart disease
This study tests a new pill called vicadrostat taken with another medicine (empagliflozin) to see if it helps people with type 2 diabetes, high blood pressure, and heart disease. It may reduce the risk of heart problems, but you must not have had heart failure or use certain other heart medications.
Anniston, AlabamaAges 18 years+ - NCT07771010RecruitingPhase 4
Comparing empagliflozin and metformin for muscle health in type 2 diabetes
This study tests two diabetes medications, empagliflozin and metformin, to see how they affect muscle energy use and blood flow in men with recently diagnosed type 2 diabetes. Participants will be followed at a diabetes clinic.
LjubljanaAges 18–75 - NCT06992440RecruitingPhase 2
Empagliflozin for better right heart function in pulmonary hypertension
This trial tests if a diabetes drug can help people with pulmonary arterial hypertension whose right heart function is reduced. Participants take empagliflozin or a placebo for 24 weeks to see if heart function improves.
Baltimore, MarylandAges 18 years+ - NCT05669742RecruitingPhase 3
Empagliflozin plus olanzapine to reduce metabolic side effects
This trial tests whether adding empagliflozin to standard olanzapine treatment can improve metabolic problems (like blood sugar and cholesterol changes) that can happen with olanzapine in people with schizophrenia. If you qualify, you would be closely monitored for benefits and side effects.
TantaAges 18–65 - NCT06483074RecruitingPhase 2
Empagliflozin to preserve kidney function in new peritoneal dialysis patients
This trial tests whether empagliflozin, a medication originally for diabetes, can help protect the remaining kidney function in people who have just started peritoneal dialysis. If you started dialysis within the last 3 months and still make some urine, this study may be a good fit.
Hong KongAges 18–75 - NCT06715449RecruitingPhase 2/Phase 3
Testing empagliflozin after a stroke with unknown cause
This trial tests if a diabetes drug called empagliflozin can help the heart's left atrium work better in people who have had a stroke with no known cause. You may join if you are getting a heart monitor device implanted to look for hidden irregular heartbeats.
Cambridge, CambridgeshireAges 18 years+ - NCT06706791RecruitingPhase 4
Empagliflozin for heart failure & diabetes: quality of life study
This trial tests whether a diabetes medicine called empagliflozin can improve the quality of life for people who have both chronic heart failure with a weak heart pump and type 2 diabetes. It compares the effects of adding empagliflozin to your current treatments.
Karachi, SindhAges 40–70 - NCT06506422RecruitingPhase 2/Phase 3
How empagliflozin may help aging arteries
This study tests if a diabetes medication, empagliflozin, can reduce age-related stiffening of arteries in people without diabetes. If you are between 60 and 80 and have stiff arteries, this trial could help improve your vascular health.
Columbia, MissouriAges 60–80 - NCT06729996RecruitingPhase 2
Comparing two diabetes medicines for pancreatitis-related diabetes
This trial tests whether pioglitazone or empagliflozin is better at managing diabetes caused by chronic or recurrent pancreatitis. You will take one of these pills daily for 6 months and track your blood sugar and ketones at home. The goal is to find a safer, more effective treatment for this type of diabetes.
Rochester, MinnesotaAges 18–80 - NCT07228195RecruitingPhase 4
Study on SGLT2i therapy after islet transplantation
This trial tests whether a diabetes medication called empagliflozin (an SGLT2 inhibitor) can help people who have had an islet transplant (TPIAT) better manage their blood sugar. It aims to see if it improves how well the transplanted islets work.
Minneapolis, MinnesotaAges 18–70 - NCT07700940RecruitingPhase 4
Empagliflozin for kidney function in lupus nephritis
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
Banī SuwayfAges 18–65
What Empagliflozin is being studied for
Conditions with recruiting Empagliflozin studies.
Common questions
- Are there clinical trials studying Empagliflozin?
- Yes. Clin2 currently lists 90 recruiting studies that include Empagliflozin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Empagliflozin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Empagliflozin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Empagliflozin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.